<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04544969</url>
  </required_header>
  <id_info>
    <org_study_id>B2019-128</org_study_id>
    <nct_id>NCT04544969</nct_id>
  </id_info>
  <brief_title>Detecting Chemosensitivity and Predicting Treatmemt Efficacy With CTCs in mNPC</brief_title>
  <official_title>Detecting Chemosensitivity and Predicting Treatmemt Efficacy With Circulating Tumour Cells From Peripheral Blood in Metastatic Nasopharyngeal Carcinoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prospective observational clinical study will recruit 50 metastatic nasopharyngeal&#xD;
      carcinoma (mNPC) patients, detecting patient's chemosensitivity with the circulating tumor&#xD;
      cells (CTCs) from peripheral blood and prdicting patient's treatment efficacy with CTCs&#xD;
      dynamic change.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Anticipated">April 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>The coincidence rate between drug sensitivity test in CTCs and objective response rate</measure>
    <time_frame>6 months</time_frame>
    <description>Comparison the coincidence rate between drug sensitivity test in CTCs and objective response rate of corresponding chemotherapy regime</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The changes of CTCs countings</measure>
    <time_frame>Change from pre-chemotherapy to 22-28(±7) days after last course of chemotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>study period of 19 Months</time_frame>
    <description>To be determined by measurement of target lesions according to RECIST criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>baseline</time_frame>
    <description>Defined as the time in months from first course of treatment until PD is observed or death occurs due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cutoff value of CTC counts</measure>
    <time_frame>Objective response at 6 months</time_frame>
    <description>to identify patients with early relapse (&lt;6 months) after liver resection as determined by the AUC under the ROC curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictive value of the changes of CTCs countings</measure>
    <time_frame>Change from pre-chemotherapy to 22-28(±7) days after last course of chemotherapy</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Circulating Tumor Cell</condition>
  <condition>Nasopharyngeal Carcinoma</condition>
  <condition>Distant Metastases.Clinical</condition>
  <condition>Effects of Chemotherapy</condition>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <description>Patients treated with palliative chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin-based chemotherapy</intervention_name>
    <description>GP: cisplatin 80 mg/m2 intravenous infusion on day1, gemcitabine 1000 mg/m2 intravenous infusion on day 1 and 8, both drugs are given every 3 weeks, recommended 6 cycles.&#xD;
TP: cisplatin 75 mg/m2 intravenous infusion in day1, docetaxel 75 mg/m2 intravenous infusion in day 1, both drugs are given every 3 weeks, recommended 6 cycles.&#xD;
PF: cisplatin 100 mg/m2 intravenous infusion in day1, fluorouracil 4000 mg/m2 intravenous infusion in day 1 to 5, both drugs are given every 3 weeks, recommended 6 cycles.&#xD;
TPF: cisplatin 60 mg/m2 intravenous infusion in day1, docetaxel 60 mg/m2 intravenous infusion in day 1, fluorouracil 3000 mg/m2 intravenous infusion in day 1 to 5, both drugs are given every 3 weeks, recommended 6 cycles.&#xD;
Choice of chemotherapy regimen is decided by patient's doctor in charge.</description>
    <arm_group_label>Chemotherapy</arm_group_label>
    <other_name>docetaxel and cisplatin</other_name>
    <other_name>fluorouracil and cisplatin</other_name>
    <other_name>docetaxel, fluorouracil and cisplatin</other_name>
    <other_name>gemcitabine and cisplatin</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        NPC patients with distant metastasis after 3 months of primary radiotherapy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  NPC patients with distant metastasis after 3 months of primary radiotherapy, and not&#xD;
             suitable for local treatment&#xD;
&#xD;
          -  At least having one measurable metastatic lesion&#xD;
&#xD;
          -  All genders，range from 18～70 years old&#xD;
&#xD;
          -  ECOG score 0 ~ 1&#xD;
&#xD;
          -  Expected survival time ≥ 3 months&#xD;
&#xD;
          -  White blood cell(WBC) count ≥ 3×109/L, neutrophile granulocyte(NE) count ≥ 1.5×109/L,&#xD;
             hemoglobin(HGB) ≥ 90g/L, platelet(PLT) count ≥ 100×109/L&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) or aspartate aminotransferase(AST) &lt; 2.5×upper limit of&#xD;
             normal(ULN), bilirubin(BUN) or creatinine(CRE) &lt; 1.5×ULN, alanine aminotransferase&#xD;
             (CCR) ≥ 60ml/min&#xD;
&#xD;
          -  Inform consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have or are suffering from other malignant tumors;&#xD;
&#xD;
          -  Participating in other clinical trials;&#xD;
&#xD;
          -  Drug or alcohol addition;&#xD;
&#xD;
          -  Do not have full capacity for civil acts;&#xD;
&#xD;
          -  Mental disorder;&#xD;
&#xD;
          -  Pregnancy or lactation;&#xD;
&#xD;
          -  Severe complication, eg, uncontrolled hypertension.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chong Zhao, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jingjing Miao, M.D</last_name>
    <phone>86-13631355201</phone>
    <email>miaojingjing90@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Center, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chong Zhao</last_name>
      <phone>02087342638</phone>
      <email>zhaochong@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.sysucc.org.cn</url>
    <description>Home Page of Cancer Center, Sun Yat-sen University</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 3, 2020</study_first_submitted>
  <study_first_submitted_qc>September 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2020</study_first_posted>
  <last_update_submitted>August 8, 2021</last_update_submitted>
  <last_update_submitted_qc>August 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Zhao Chong</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
    <mesh_term>Neoplastic Cells, Circulating</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

